Liquid biopsy has arrived at a pivotal moment in cancer diagnostics. What began as an experimental concept — the idea that a simple blood draw could reveal the genetic secrets of a tumor — has matured into a $3.6 billion global market in 2025. Today, clinicians use blood-based tests to detect cancer early, monitor treatment response in real time, identify molecular relapse before it becomes visible on a scan, and guide precision therapy decisions. The technology is embedded in national health systems, supported by billions in research funding, and the subject of some of the largest corporate acquisitions in diagnostics history.
But the field did not arrive here overnight. The journey from early-stage curiosity to clinical standard involves a decade of regulatory milestones, technology breakthroughs, institutional investment, and a fundamental rethinking of how cancer is diagnosed and managed. This article traces that path.
In 2012, liquid biopsy for therapy guidance was present in clinical trials, but only barely. Fewer than ten such trials existed at that point, reflecting a field still in the proof-of-concept stage. Researchers understood that circulating tumor DNA — fragments shed by tumors into the bloodstream — carried potentially actionable information, but the tools to read that information reliably, at scale, and at acceptable cost were not yet mature.
The clinical case for liquid biopsy was conceptually compelling from the start. Traditional tissue biopsy, the diagnostic gold standard, requires invasive procedures, carries procedural risks, and provides only a snapshot of one tumor site. For cancers in difficult-to-reach locations, tissue sampling may not even be feasible. A blood draw that could capture the same molecular information — and be repeated as often as needed — offered obvious advantages. The challenge was building the assay technology and clinical evidence to back up that promise.
Through the mid-to-late 2010s, several converging forces transformed liquid biopsy from a research curiosity into a credible diagnostic platform. Next-generation sequencing costs fell dramatically, making comprehensive molecular profiling from small quantities of circulating tumor DNA economically viable. Digital PCR emerged as a complement, enabling absolute quantification of rare mutations at variant allele frequencies as low as 0.1% — a level of sensitivity that conventional methods could not reliably achieve.
Alongside the technology, clinical validation work intensified. Companies including Guardant Health, Foundation Medicine, and Natera developed assay platforms and began accumulating the evidence base that regulatory agencies and payers would eventually require. The practical advantages of liquid biopsy — repeat testing, real-time monitoring, comprehensive capture of tumor heterogeneity across metastatic sites — became increasingly apparent as oncology moved toward precision medicine frameworks that demanded continuous biomarker information rather than a single static measurement.
By 2022, the numbers told a clear story of progress. Clinical trials using liquid biopsy for therapy guidance had grown from fewer than 10 in 2012 to approximately 40 — a fourfold increase in a decade. Eighteen tests had received approval as in vitro diagnostics, with 47 more available as laboratory-developed tests. The regulatory pathway, while still demanding, was no longer theoretical; it had been traveled successfully by multiple assay developers across multiple cancer indications.
This period also saw the application landscape broaden. Early adoption had been concentrated in therapy monitoring — using serial ctDNA measurements to track treatment response — but recurrence monitoring and companion diagnostic applications were gaining traction. The ability to detect molecular residual disease after surgery, potentially months before clinical relapse would appear on imaging, represented a genuinely new capability that tissue biopsy could not replicate.
In October 2023, UCLA researchers received a five-year, $4.6 million grant from the National Cancer Institute to advance liquid biopsy technologies for early lung cancer detection. The award was one signal among many that major research institutions had moved from cautious interest to active investment in blood-based diagnostics.
The following year brought structural changes at the company level. In 2024, Illumina completed the spin-off of GRAIL, which began trading independently on Nasdaq under the ticker GRAL, with Illumina retaining a 14.5% minority stake. GRAIL had developed the Galleri test, capable of detecting signals from more than 50 cancer types from a single blood draw — a multi-cancer early detection approach that extended liquid biopsy's potential reach from individual cancer management to population-scale screening programs. Separating GRAIL as an independent entity reflected the scale of ambition behind that vision and the distinct commercial path multi-cancer early detection was beginning to chart.
Also in 2024, Foundation Medicine received multiple FDA approvals for FoundationOne Liquid CDx as a companion diagnostic, expanding its coverage to breast cancer cases with PIK3CA mutations and prostate cancer cases with BRCA mutations. Each companion diagnostic approval expanded the defined patient population for whom a liquid biopsy test had explicit clinical utility and regulatory backing.
Several developments in 2025 marked a shift from validation to broader clinical integration. NHS England introduced liquid biopsy testing through its Genomic Test Directory for lung cancer and advanced breast cancer — becoming the first health system to routinely prioritize blood-based testing over traditional tissue biopsy in these indications. The NHS move signaled that liquid biopsy had cleared the evidence threshold required for health system adoption at scale, at least for specific indications.
On the reimbursement front in the United States, Natera's Signatera received CMS MolDX coverage for minimal residual disease surveillance in stage I to III non-small cell lung cancer. Medicare reimbursement for ctDNA-based recurrence monitoring in NSCLC removed one of the most significant barriers to adoption for a major lung cancer patient population.
The year also produced the largest corporate transaction in the market's history. Abbott Laboratories announced an agreement to acquire Exact Sciences for approximately $21 billion, combining Abbott's diagnostics infrastructure with Exact Sciences' cancer screening and precision oncology portfolio. The scale of that deal communicated the commercial confidence that major diagnostics companies now attach to liquid biopsy as a long-term growth category.
In 2026, India launched the National Cancer Clinical Trials Alliance and the Liquid Biopsy Foundation of India, two initiatives aimed at expanding cancer care infrastructure and improving access to blood-based diagnostics across the country. The move reflected a broader pattern of government-led efforts to build liquid biopsy capacity in large patient populations outside established Western markets.
Also in 2026, Dxcover received CE-IVDR Class C certification in Europe for its AI-enabled liquid biopsy diagnostic device, validating the technology for broader clinical deployment across multiple cancer detection applications on the continent.
The global liquid biopsy market stood at $3.6 billion in 2025 and is projected to reach $8.0 billion by 2031, growing at a CAGR of 14.1% from 2026 to 2031.
By technology, next-generation sequencing dominates with 73.6% revenue share and a market value of $2.7 billion in 2025, growing at 14.5% CAGR. PCR contributes $520.0 million at 13.5% CAGR, supported by the rising adoption of digital PCR for ultra-sensitive ctDNA detection. Among biomarker types, circulating nucleic acids account for 82.3% of the market at $2,998.7 million, while exosomes represent the fastest-growing segment at 15.8% CAGR.
Lung cancer is the leading indication at $1,126.5 million and 30.9% market share, driven by disease burden and the maturity of liquid biopsy adoption in non-small cell lung cancer. Colorectal cancer is the fastest-growing indication at 15.7% CAGR, supported by strong ctDNA adoption, MRD detection, and expanding screening programs. Therapy monitoring is the largest application at $1,451.6 million, while early cancer screening is the fastest-growing application at 15.7% CAGR.
North America leads all regions with 48.4% of global revenue, supported by advanced infrastructure, established reimbursement frameworks, and the presence of companies including Guardant Health, Natera, and Exact Sciences. Asia-Pacific is the fastest-growing region at a CAGR of 16.2%, driven by rising cancer burden, large patient populations, and government support for precision diagnostics.
Several forces will shape the next phase of growth. Multi-cancer early detection tests represent the most significant expansion of the market's addressable population — products such as GRAIL's Galleri and Exact Sciences' CancerGuard extend liquid biopsy's reach from cancer management into population-scale screening for average-risk adults. As clinical evidence accumulates and regulatory pathways clarify, MCED tests could substantially enlarge both the testing volume and the commercial scale of the market.
Artificial intelligence is becoming integral to liquid biopsy's clinical utility. Platforms from companies including Novigenix AI and Dxcover apply machine learning to extract cancer signals from complex multi-omic datasets that would be indecipherable through conventional analysis. AI enables earlier detection of low-burden tumors, improves sensitivity and specificity, and makes the data generated by liquid biopsy assays actionable in clinical time frames.
Exosome-based diagnostics and cfDNA methylation analysis represent two biomarker frontiers gaining clinical traction. Exosomes offer high stability, rich biomarker content, and the potential for organ-specific cancer signals beyond what ctDNA alone can provide. Methylation profiling enables tissue-of-origin identification alongside cancer detection, which is critical for multi-cancer screening applications where knowing which cancer type is present is as important as knowing a signal exists.
Multi-omics integration — combining genomic, epigenomic, transcriptomic, proteomic, and immune profiling data from a single blood sample — addresses the limitations of single-biomarker approaches and is increasingly central to comprehensive tumor characterization. Platforms from Guardant Health, Personalis, and Freenome are advancing this capability toward clinical application.
The primary challenges ahead involve standardization, reimbursement, and sensitivity at early-stage disease. Without consistent protocols across laboratories, clinical reliability remains uneven. Reimbursement coverage remains inconsistent across markets, particularly in Europe and low- and middle-income countries. And while liquid biopsy's performance in advanced disease is well-established, improving sensitivity for early-stage cancers where circulating biomarker concentrations are minimal remains the defining technical challenge for the field.
Liquid biopsy has traveled a remarkable distance in roughly a decade — from a handful of clinical trials to a multi-billion-dollar market embedded in national health systems, precision oncology frameworks, and some of the largest M&A transactions in diagnostics history. The arc of development has been driven by technology maturation, clinical evidence accumulation, regulatory progress, and a sustained shift in oncology toward dynamic, repeatable, noninvasive biomarker testing.
The next phase will be defined by how broadly multi-cancer early detection reaches average-risk populations, how effectively AI and multi-omics integration improve diagnostic accuracy, and how successfully the industry resolves the reimbursement and standardization barriers that still limit access in many markets. The foundation is built. What the market becomes from here depends on execution against those remaining challenges.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.